Biotron Share Price Competition Jan 1 2022, page-296

Sure.
That is a quick question that really needs a long in-depth answer, however, I will attempt brevity.
Biotron:
- Uses a piddling amount of money to achieve verifiable results with world class labs.
- Somehow has squeezed that tiny budget to produce about a dozen high quality human trials.
- Refuses to report positive findings without many caveats, so much so that the share price actually plummets on good news, despite achieving goals and producing positive results. I like that in a scientist.
- Went for the hard target, (E protein), instead of targeting the rapidly mutating Covid Spike Protein and if this all goes the way I am reading it, that could result in saving lives due to the effect on the cytokine storm. It is not just a quick stop-gap cashing in on a temporary solution.

That is just the top of the list. Quoting from the papers produced and used in other papers is a massive job that does not appear to appreciated on here, so forgive me if I do not go further.